TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12826992
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg/day)
Study: 10403850
Drug: Neostigmine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (2.0 mg intravenously)
Study: 8899087
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 1000 mg plus vitamin D 250 IU (Oscal)
Study: 1647337
Drug: Pyridostigmine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine, 30 mg three times daily for 10 days
Study: 1647337
Drug: Placebo, similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, similar dosage and duration as treatment group
Study: 31335802
Drug: Oral tenofovir‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tenofovir‐based pre‐exposure prophylaxis (PrEP)
Study: 30037068
Drug: Resveratrol (RSV)
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (RSV) 500 mg/day
Study: 27372432
Drug: Selective COX-2
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective COX-2 inhibitor etoricoxib
Study: 23390784
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection of 20 ml 0.25% bupivacaine
Study: 23390784
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution (control)
Study: 15915026
Drug: Active nicotine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nicotine-containing patches
Study: 9252901
Drug: 13C-xylose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13C-xylose (50 mg)
Study: 9252901
Drug: Control groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control groups (10 mg and 25 mg 13C-xylose)
Study: 8391042
Drug: Lymphoblastoid interferon
Normalized name: interferon alfa-n1 lymphoblastoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoblastoid interferon (administered in a step-down schedule for 12 months)
Study: 3505532
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg oral administration)
Study: 29335043
Drug: Endoscopic repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic repair using a mirrored L‐shaped flap without stenting (Group A)
Study: 28410809
Drug: Radiotherapy 60Gy/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy 60Gy/30 fractions with oral vinorelbine 50mg 3 times weekly
Study: 28410809
Drug: Radiotherapy 66Gy/33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy 66Gy/33 fractions with oral vinorelbine 50mg 3 times weekly
Study: 26154736
Drug: Posterior subtenon's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior subtenon's injection of 40 mg of triamcinolone acetonide
Study: 26154736
Drug: Grid laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grid laser photocoagulation (GLP) combined with posterior subtenon's triamcinolone injection
Study: 23496861
Drug: Nicotine e-cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine e-cigarettes (16 mg)
Study: 21680726
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control therapy (IT) for 2 weeks
Study: 15012688
Drug: Low GDP
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low GDP solution (pH 7.0)
Study: 15012688
Drug: High GDP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High GDP solution (pH 5.5)
Study: 9085977
Drug: BIS-guided group
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-guided group (anesthetic drug doses increased to produce a lower BIS)
Study: 8441793
Drug: SAMe 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe 1,600 mg/day
Study: 31080092
Drug: Telephone peer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone peer coaching (weekly 30-min calls for 6 months)
Study: 16275243
Drug: Oxiplex/AP Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiplex/AP Gel
Study: 9857882
Drug: Sarpogrelate 200
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate 200 mg orally administered
Study: 2228077
Drug: Indomethacin suppositories
Normalized name: Indomethacin Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppositories (100 mg 1‐3 times a day)
Study: 26375
Drug: Pilocarpine 4%
Normalized name: PILOCARPINE 4% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine 4% solution at pH 4.1
Study: 26375
Drug: Pilocarpine 4%
Normalized name: PILOCARPINE 4% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine 4% solution at pH 5.8
Study: 15168040
Drug: High intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intake diet (810 g/10 MJ of vegetables, berries, and apple)
Study: 15168040
Drug: Low intake
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intake diet (196 g/10 MJ of vegetables, berries, and apple)
Study: 11248360
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (300 mg twice daily for 3 months)
Study: 9676168
Drug: PTCA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTCA plus heparin-coated stent (n = 202)
Study: 2573301
Drug: Systemically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemically administered terfenadine
Study: 2573301
Drug: Systemically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemically administered cetirizine
Study: 29247107
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone (0.5 mg/kg daily) plus rituximab (375 mg/m2 weekly)
Study: 29247107
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone (1 mg/kg daily) plus rituximab
Study: 26011742
Drug: Crushed ALO-02
Normalized name: miconazole nitrate 0.02 MG/MG [Aloe Vesta Antifungal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed ALO-02 (30 mg oxycodone/3.6 mg naltrexone)
Study: 26011742
Drug: Oxycodone immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone immediate-release (IR) (30 mg)
Study: 10360713
Drug: Monthly measurement
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly measurement of access flow (QAT)
Study: 10360713
Drug: Monthly measurement
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly measurement of static venous pressure (VPS)
Study: 10360713
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no monthly monitoring)
Study: 2008802
Drug: Vaccine A
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine A (oral, 3 doses at 14-day intervals)
Study: 2008802
Drug: Vaccine B
Normalized name: meningococcal vaccine B and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine B (oral, 3 doses at 14-day intervals)
Study: 2008802
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 ml 5% NaHCO3, oral, 3 doses at 14-day intervals)
Study: 29580634
Drug: D-Cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-Cycloserine (DCS) 100 mg
Study: 28832388
Drug: Non‐op treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐op treatment
Study: 28832388
Drug: OP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP treatment with hook plate fixation
Study: 25823991
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g Fibersol-2
Study: 25823991
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g Fibersol-2 (Control)
Study: 25823991
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g Fibersol-2
Study: 15036674
Drug: Neoadjuvant cisplatinum
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant cisplatinum based combination chemotherapy (with adriamycin or methotrexate)
Study: 9612112
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment of factor XIII twice daily for ten days (treatment group, n = 16)
Study: 7838916
Drug: R10 min/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: R10 min/3 mg
Study: 7838916
Drug: R1h/5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1h/5 mg
Study: 7838916
Drug: R4h/9 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: R4h/9 mg
Study: 3377148
Drug: Nalbuphine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.05 mg/kg combined with midazolam 0.05 mg/kg
Study: 3377148
Drug: Nalbuphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.1 mg/kg combined with midazolam 0.05 mg/kg
Study: 3377148
Drug: Nalbuphine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.2 mg/kg combined with midazolam 0.05 mg/kg
Study: 3377148
Drug: Nalbuphine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.05 mg/kg
Study: 26174719
Drug: Pharmacogenetic arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacogenetic arm (200 mg of atazanavir twice daily for patients with unfavourable genotypes)
Study: 26174719
Drug: Standard-dose arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose arm (400 mg of atazanavir once daily)
Study: 20840347
Drug: synchronous balneophototherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: synchronous balneophototherapy (sBPT) consisting of narrowband UVB PT with 311 nm and synchronous bathing in 10% Dead Sea salt solution
Study: 19819665
Drug: SC morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC morphine plus rHuPH20 (150U)
Study: 19819665
Drug: SC morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC morphine plus placebo (normal saline)
Study: 16723653
Drug: Implant Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant Group (n = 62)
Study: 15622663
Drug: Parecoxib 20
Normalized name: parecoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib 20 mg i.m.
Study: 1931399
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg i.m.
Study: 11689738
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (20 g x d(‐1) for 5 days, then 5 g x d(‐1) for 5 days)
Study: 11689738
Drug: Placebo (cornstarch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cornstarch, same dosage regimen as Cr group)
Study: 31218889
Drug: Run Zao
Normalized name: Zaocys dhumnades preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run Zao Zhi Yang capsule (RZZYC)
Study: 31218889
Drug: Run Zao
Normalized name: Zaocys dhumnades preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run Zao Zhi Yang capsule (RZZYC) and Placebo
Study: 29192639
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg ropivacaine 1%
Study: 29192639
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ropivacaine 1%
Study: 29192639
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg ropivacaine 1%
Study: 26562074
Drug: PEMF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEMF treatment (MAGCELL ARTHRO device), delivered a sinusoidal magnetic field of 4-12 Hz, magnetic flux density of 105 mT, treatment twice a day for 5 min over 18 days.
Study: 26562074
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (placebo device)
Study: 26562074
Drug: PEMF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEMF treatment
Study: 23415013
Drug: Clopidogrel alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel alone (double therapy)
Study: 23415013
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (triple therapy)
Study: 30879003
Drug: AZD1981 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1981 40 mg TID
Study: 29299989
Drug: Curcumin 1000mg
Normalized name: Radiance Platinum Turmeric Curcumin 1000mg Capsule
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 1000mg with 10mg of piperine daily
Study: 27195662
Drug: Best contemporary
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best contemporary metallic drug-eluting stents (DES)
Study: 24843205
Drug: G-Bone® (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bone® (modified hydroxyapatite)
Study: 17965442
Drug: C5aR-antagonist AcF-(OpdChaWR)
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: C5aR-antagonist AcF-(OpdChaWR) (PMX53)
Study: 11753768
Drug: Passive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive treatment or no treatment
Study: 9586884
Drug: Standard-dose cranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cranial irradiation (SRT) of 36 Gy
Study: 9586884
Drug: Reduced-dose cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose cranial irradiation (RRT) of 23.4 Gy
Study: 2645441
Drug: Saphenous vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saphenous vein patch closure (n = 62)
Study: 25809413
Drug: Prednisone at
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone at 0.75 mg/kg/day
Study: 8750372
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of losartan 50 mg and hydrochlorothiazide 12.5 mg
Study: 23496265
Drug: Maximum dose
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum dose of losartan (100 mg)
Study: 19457937
Drug: ITP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITP regimen (ifosfamide 1.5 g/m² daily on days 1-3, cisplatin 70 mg/m² on day 2, paclitaxel 175 mg/m² on day 1)
Study: 19457937
Drug: IP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP regimen (ifosfamide 1.5 g/m² daily on days 1-3, cisplatin 70 mg/m² on day 2)
Study: 16393594
Drug: Single one‐pass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single one‐pass pulsed dye laser treatment (595 nm, 7 J/cm2 fluence, 7 mm spot size, 1.5‐millisecond pulse duration, 30‐millisecond spray, 20‐millisecond delay of dynamic cooling) at the time of suture removal (2 weeks after excision)
Study: 16393594
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment with laser)
Study: 3158674
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg bid
Study: 29333721
Drug: 60 g·h‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g·h‐1 (LG)
Study: 29333721
Drug: 75 g·h‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g·h‐1 (HG)
Study: 29333721
Drug: 90 g·h‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g·h‐1 (LGF)
Study: 29333721
Drug: 112.5 g·h‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 112.5 g·h‐1 (HGF)
Study: 29333721
Drug: 90 g·h‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g·h‐1 glucose-fructose ingestion
Study: 17574461
Drug: Zonisamide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (mean maintenance dosage 7.7 mg/kg/day, range: 4-16 mg/kg/day)
Study: 12502672
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg daily
Study: 21309844
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg daily
Study: 10190650
Drug: Salbutamol (beta2-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (beta2-adrenoceptor partial agonist)
Study: 10190650
Drug: ICI 118,551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551 (beta2-adrenoceptor antagonist)
Study: 1979207
Drug: Levocabastine eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine eye drops (0.5 mg/ml solution)
Study: 23380515
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume (Hi-TV) of 10 mL/kg, rate of 7 breaths/min, zero positive end-expiratory pressure
Study: 23380515
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (Lo-TV) of 5 mL/kg, rate of 14 breaths/min, 5 cmH2O positive end-expiratory pressure
Study: 21317598
Drug: Buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone treatment integrated with HIV care
Study: 11605710
Drug: Anthroposophic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthroposophic therapy
Study: 11605710
Drug: Conventional cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cancer treatment
Study: 9526967
Drug: Chlordiazepoxide (CDP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (CDP, Librium) 5 mg
Study: 9526967
Drug: Chlordiazepoxide (CDP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (CDP, Librium) 20 mg
Study: 7510813
Drug: Lenograstim 5
Normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim 5 micrograms/kg per day by 30-min infusion for 28 days or until neutrophil recovery
Study: 2530384
Drug: h-alpha ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: h-alpha ANP infusion
Study: 1234013
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (300 mug cumulative dose in three injections over 45 min)
Study: 6795701
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage of ftorafur (2 g/m2/day X 5 days)
Study: 6795701
Drug: 5‐FU combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU combination chemotherapy
Study: 29346597
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 μg twice a day for 12 weeks
Study: 24290606
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3 g/d) and kinako (29.14 g/d)
Study: 24290606
Drug: Kinako (29.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinako (29.14 g/d)
Study: 17625977
Drug: 10% solution
Normalized name: Mucomyst 10% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% solution of 15 g fructose
Study: 17625977
Drug: 10% solution
Normalized name: Mucomyst 10% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% solution of 25 g fructose
Study: 17625977
Drug: 10% solution
Normalized name: Mucomyst 10% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% solution of 50 g fructose
Study: 17625977
Drug: 33% solution
Normalized name: Dextrose 5%, Sodium Chloride 0.33% Solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33% solution of 50 g fructose
Study: 17625977
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of doses
Study: 15989703
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) at 250 mg/m2 per day, starting 24 hours after completion of chemotherapy and continuing up to 48 hours before the next cycle.
Study: 15989703
Drug: Fludarabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine and cyclophosphamide combination treatment.
Study: 9833957
Drug: Nucleoside therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside therapy combined with a protease inhibitor (zidovudine + lamivudine + indinavir)
Study: 9833957
Drug: Nucleoside therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside therapy alone
Study: 353969
Drug: Trimipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (50 mg daily before bedtime)
Study: 26447155
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1.8 g/d for 4 weeks
Study: 21812266
Drug: Qumin Tongbi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qumin Tongbi Nasal Spraying Agent (QTNSA)
Study: 9250258
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin (20,000 units)
Study: 9250258
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin (25 U/kg)
Study: 8422173
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (surgical adjuvant chemotherapy with 12 mg/m2 of MMC on the day of operation, followed by 6 mg/m2 every 2 months for 6 times, and 800 mg/day of Futraful for one year)
Study: 8422173
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (surgical adjuvant chemotherapy)
Study: 8422173
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (no treatment)
Study: 27673437
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Endoscopic sinus surgery)
Study: 25601535
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal ranibizumab 0.3 mg
Study: 23967634
Drug: Acupuncture +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture + medication (Shugan Jianwei Anshen Decoction + acupuncture daily at specific points)